X0202 SCHEDULE 13G/A 0001415889-25-009648 0001873545 XXXXXXXX LIVE 1 Common Stock, $0.0001 par value per share 03/31/2026 0001824893 Surrozen, Inc. 86889P208 171 OYSTER POINT BLVD SUITE 400 SOUTH SAN FRANCISCO CA 94080 Rule 13d-1(c) 5AM Partners VII, LLC b DE 0.00 1162500.00 0.00 1162500.00 1162500.00 9.5 OO 5AM Ventures VII, L.P. b DE 0.00 1162500.00 0.00 1162500.00 1162500.00 9.5 PN Kush Parmar b X1 0.00 1162500.00 0.00 1162500.00 1162500.00 9.5 IN Andrew J. Schwab b X1 0.00 1162500.00 0.00 1162500.00 1162500.00 9.5 IN Surrozen, Inc. 171 OYSTER POINT BLVD, SUITE 400, SOUTH SAN FRANCISCO, CA, 94080. The names of the persons filing this report (collectively, the "Reporting Persons") are: 5AM Ventures VII, L.P. ("Ventures VII") 5AM Partners VII, LLC ("Partners VII") Andrew J. Schwab ("Schwab") Kush Parmar ("Dr. Parmar") The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G/A. c/o 5AM Ventures 4 Embarcadero Center, Suite 3110 San Francisco, CA 94111 Ventures VII Delaware Partners VII Delaware Schwab United States Parmar United States Y Row 9 of each Reporting Person's cover page to this Schedule 13G/A sets forth the aggregate number of securities of the Issuer beneficially owned by such Reporting Person and is incorporated by reference. Ventures VII directly holds (i) 387,500 shares of common stock; and (ii) common warrants (the "Warrants") exercisable for up to 77,500 shares of common stock. In addition, pursuant to the Securities Purchase Agreement dated March 24, 2025 by and among the Issuer and certain investors, including Ventures VII (the "Purchase Agreement"), Ventures VII has agreed to purchase an additional (i) 465,000 shares of the Issuer's common stock (the "2nd Closing Shares") and (ii) common warrants (the "2nd Closing Warrants" and, together with the 2nd Closing Shares, the "2nd Closing Securities") exercisable for up to 232,500 shares of common stock in a second closing under the Purchase Agreement upon the Issuer's achievement of a regulatory milestone on or prior to October 31, 2026. In the event that the Issuer terminates its SZN-8141 development program prior to October 31, 2026, then the Issuer is required to provide the investors under the Purchase Agreement, including Ventures VII, with a notice (the "Termination Notice"), after which Ventures VII would have the right, but not the obligation, to purchase the 2nd Closing Securities within the following 30 calendar days. Finally, at any time prior to the earlier of October 31, 2026 or the date of a Termination Notice, Ventures VII has the right, but not the obligation, to purchase all (but not a portion) of the 2nd Closing Securities. By virtue of this right, Ventures VII is considered to beneficially own the 2nd Closing Shares and the shares issuable upon exercise of the 2nd Closing Warrants. Partners VII is the sole general partner of Ventures VII and Schwab and Dr. Parmar are the managing members of Partners VII. Each of Partners VII, Schwab and Dr. Parmar shares voting and dispositive power over the securities held by Ventures VII. Each Reporting Person beneficially owns 9.5% of the Issuer's common stock, which percentage is based upon 11,486,707 shares of the Issuer's common stock outstanding as of March 18, 2026, as reported in the Issuer's definitive proxy statement filed with the Securities and Exchange Commission (the "SEC") on April 1, 2026, adjusted to give effect to the Warrants, 2nd Closing Shares and 2nd Closing Warrants to the extent that such securities may be acquired and exercised within 60 days hereof, as referenced herein. Row 5 of each Reporting Person's cover page to this Schedule 13G/A sets forth the sole power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person as of March 31, 2026 and is incorporated by reference. Row 6 of each Reporting Person's cover page to this Schedule 13G/A sets forth the shared power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person as of March 31, 2026 and is incorporated by reference. Row 7 of each Reporting Person's cover page to this Schedule 13G/A sets forth the sole power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person as of March 31, 2026 and is incorporated by reference. Row 8 of each Reporting Person's cover page to this Schedule 13G/A sets forth the shared power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person as of March 31, 2026 and is incorporated by reference. Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Exhibit 99.1 Joint Filing Agreement (incorporated by reference to Exhibit 99.1 to the Reporting Persons' Schedule 13G filed with the SEC on April 2, 2025). 5AM Partners VII, LLC /s/ Andrew J. Schwab 05/15/2026 5AM Ventures VII, L.P. /s/ Andrew J. Schwab 05/15/2026 Kush Parmar /s/ Kush Parmar 05/15/2026 Andrew J. Schwab /s/ Andrew J. Schwab 05/15/2026